Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck

Cancer Biology and Therapy

Volumn 9, Issue 5, 2010, Pages 343-349

  Rodríguez, Marta Osorio ^a   Rivero, Teresa Cruz ^a   Bahi, Ramón Del Castillo ^a   Muchuli, Carlos Roca ^a   Bilbao, Miguel Azcue ^a   Vinageras, Elia Neninger ^b   Alert, José ^a   Galainena, Julio Jiménez ^a   Rodríguez, Edmundo ^a   Gracias, Elías ^a   Mulén, Bárbara ^b   Wilkinson, Bárbara ^d   De Armas, Esther Lucía ^c   Pérez, Kirenia ^c   Pineda, Idael ^d   Frómeta, Milagros ^d   Leonard, Idrissa ^d   Mullens, Vladimir ^d   Viada, Carmen ^d   Luaces, Patricia ^d   Torres, Olga ^d   Iznaga, Normando ^d   Crombet, Tania ^d   more..

^a INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^b HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

^c Hospital Celestino Hernandez Robau   (Cuba)

^d CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Epidermal growth factor receptor; Immunotherapy; Monoclonal antibody; Nimotuzumab; Squamous cell carcinoma of the head and neck; Targeted therapy

Indexed keywords

NIMOTUZUMAB;

ADULT; ANOREXIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FEVER; HEAD AND NECK CANCER; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; SQUAMOUS CELL CARCINOMA;

ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EXANTHEMA; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS;

EID: 77953694219     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.5.10981     Document Type: Article

References (27)

1. Michiels S, Le Maître A, Buyse M, Burzykowski T, Maillard E, Bogaerts J, et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta- analyses of individual patient data. Lancet Oncol 2009; 10:6-8.
2. Burri RJ, Lee NY. Concurrent chemotherapy and radiotherapy for head and neck cancer. Expert Rev Anticancer Ther 2009; 9:293-302.
3. Hama T, Yuza Y, Saito Y, O-uchi J, Kondo S, Okabe M, et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 2009; 14:900-8.
4. Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 2009; 115:922-35.
5. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3:71-81.
6. Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002; 101:567-75.
7. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61:5090-101.
8. Diaz Miqueli A, Blanco R, Garcia B, Badia T, Batista AE, Alonso R, et al. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma 2007; 26:423-31.
9. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22:1646-54.
10. Ramakrishnan M, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs 2009; 1:41-8.
11. Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 2000; 87:881-6.
12. Withers HR, Peters LJ, Taylor JM, Owen JB, Morrison WH, Schultheiss TE, et al. Local control of carcinoma of the tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions. Int J Radiat Oncol Biol Phys 1995; 33:549-62.
13. Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009; 69:5851-9.
14. Crombet T, Figueredo J, Catala M, González S, Selva JC, Cruz TM, et al. Treatment of high-grade glioma patients with the humanized anti-EGFR MAb h-R3: report from a phase I/II trial. Cancer Biol Ther 2006; 5:375-9.
15. Gondhowiardjo S, Muthalib A, Khotimah S, Rachman A. Nimotuzumab combined with radiotherapy reduces primary tumor and nodal volume in advanced undifferentiated nasopharyngeal carcinoma. Asia-Pacific J Clin Oncol 2009; 5:175-80.
16. Fountzilas G, Kosmidis P, Avramidis V, Nikolaou A, Kalogera-Fountzila A, Makrantonakis P, et al. Long-term survival data and prognostic factors of a complete response to chemotherapy in patients with head and neck cancer treated with platinum-based induction chemotherapy: a Hellenic Co-operative oncology Group study. Med Pediatr Oncol 1997; 28:401-10.
17. Winquist E, Nabid A, Sicheri A, Ganguly P, Venkatesan V, Schneider K, et al. A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). Proc Am Soc Clin Oncol 2002; 21:926.
18. Fine G. Consequences of delayed treatment effects on analysis of time to events endpoints. Drug Inf J 2007; 41:535-9. (Pubitemid 47041925)
19. Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Lessons from randomized phase III studies with active cancer immunotherapies-outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007; 25:97-109.
20. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12:864-72.
21. Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, et al. C-100-21 Study Group. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008; 26:955-62.
22. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a Phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21-8.
23. Ri Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood 2009; 113:3809-12.
24. Garrido G, Lorenzano P, Sánchez B, Beausoleil I, Alonso DF, Pérez R, et al. T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. Cancer Immunol Immunother 2007; 56:1701-10.
25. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-78.
26. Giro C, Berger B, Bölke E, Ciernik IF, Duprez F, Locati L, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORT institutes. Radiother Oncol 2009; 90:166-71.
27. Rojo F, Gracias E, Villena N, Cruz T, Corradino I, Cedeño M, et al. Pharmacodynamic study of nimotuzumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), in patients with unresecTable squamous cell carcinoma of the head and neck (SCCHN): A SENDO Foundation study. J Clin Oncol 2008; 26:6070.